Related Experiment Video

Updated: Sep 30, 2025

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective
06:14

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective

Published on: January 12, 2024

2.1K

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?

C Meurot1, C Jacques2, C Martin1

  • 14P-Pharma, Lille, France.

Journal of Orthopaedic Translation
|March 14, 2022
PubMed

Insights

Glucagon-like peptide-1 receptor (GLP-1R) therapies show promise for osteoarthritis (OA) due to their anti-inflammatory effects. These incretin-based treatments may offer a new disease-modifying approach for OA patients.

Area of Science:

  • Molecular biology
  • Immunology
  • Pharmacology

Background:

  • Osteoarthritis (OA) is a degenerative joint disease impacting millions globally.
  • Joint cells in OA are activated by mechanical stress, inflammation, and matrix disorganization.
  • Current OA treatments lack disease-modifying capabilities.

Purpose of the Study:

  • To review the role of the Glucagon-like peptide-1 receptor (GLP-1R) pathway in osteoarthritis.
  • To explore the potential of GLP-1 analogues as disease-modifying osteoarthritis drugs (DMOADs).

Main Methods:

  • Review of existing literature on GLP-1R signaling.
  • Analysis of molecular mechanisms and cellular phenotypes in OA pathogenesis.
  • Examination of the anti-inflammatory, immunomodulatory, and differentiation properties of GLP-1 analogues.

Main Results:

  • GLP-1 receptor activation exhibits pleiotropic effects, including immunomodulation and anti-inflammation.
  • GLP-1 analogues possess properties beneficial for OA treatment.
  • The GLP-1R pathway is implicated in OA pathogenesis.

Conclusions:

  • GLP-1-based therapies, owing to their anti-inflammatory actions, could be beneficial for OA patients.
  • GLP-1 analogues represent potential disease-modifying osteoarthritis drugs (DMOADs).
  • Further research into GLP-1R pathways may uncover novel therapeutic strategies for OA.
Keywords:
CartilageGlucagon-like peptide-1 (GLP-1)Glucagon-like peptide-1 receptor (GLP-1R)LiraglutideOsteoarthritisSynovial tissue

More Related Videos

Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs12:44

Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs

Published on: January 27, 2023

4.0K
The Monoiodoacetate Model of Osteoarthritis Pain in the Mouse09:26

The Monoiodoacetate Model of Osteoarthritis Pain in the Mouse

Published on: May 16, 2016

36.0K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
454
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.8K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
231
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.5K
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
277